Darunavir

Key facts

Invented name
Prezista
Active substance
darunavir
Therapeutic area
Infectious diseases
Decision number
P/138/2010
PIP number
Darunavir
Pharmaceutical form(s)
  • Film-coated tablet
  • Oral suspension
Condition(s) / indication(s)
Treatment of human immunodeficiency virus (HIV-1) infection
Route(s) of administration
Oral use
Contact for public enquiries
Janssen-Cilag International NV
E-mail: info@its.jnj.com
Country: Belgium
Phone: +32 15293100
Fax: +32 15286347
Decision type
PM: decision on the application for modification of an agreed PIP
Compliance procedure number
EMEA-C-000038-PIP01-07-M03
Compliance opinion date
13/12/2011
Compliance outcome
positive

Decision

How useful was this page?

Add your rating